Voyager Therapeutics Announces New Data at the American Society of Gene and Cell Therapy 2018 Annual Meeting
May 17, 2018 18:15 ET
|
Voyager Therapeutics, Inc.
VY-SOD101 achieves meaningful suppression of disease-causing gene of ALS in large mammals after a one-time administration Results during the second half of 2018 from further delivery optimization...
Voyager Therapeutics Announces First Quarter 2018 Financial Results and Corporate Highlights
May 10, 2018 07:04 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., May 10, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
Wave Life Sciences and Takeda Form Global Strategic Collaboration to Advance Therapies for Central Nervous System Disorders
February 20, 2018 07:00 ET
|
Wave Life Sciences
Wave to receive at least $230 million, including $110 million in upfront cash, $60 million in equity investment and at least $60 million in research support Takeda to receive option to co-develop...
Vaccinex, Inc. to Host Key Opinion Leader Luncheon on Huntington’s Disease
January 30, 2018 11:14 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Jan. 30, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a privately-held clinical-stage biotechnology company engaged in the discovery and development of human therapeutic monoclonal...
Emerald Health Therapeutics’ Scientific Advisors Publish Research Discovery of THCA Cannabinoid’s Neuroprotective Treatment Potential
September 20, 2017 07:00 ET
|
Emerald Health Therapeutics Inc.
VICTORIA, British Columbia, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics Inc. (EHT) (TSXV:EMH) (OCTQX:EMHTF), a Canadian licensed medical producer of cannabis, is pleased to report...
Voyager Therapeutics Reports Second Quarter 2017 Financial Results and Corporate Highlights
August 08, 2017 07:05 ET
|
Voyager Therapeutics
CAMBRIDGE, Mass., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological...
Voyager Therapeutics Selects Lead Clinical Candidate for Huntington’s Disease
June 01, 2017 07:04 ET
|
Voyager Therapeutics
CAMBRIDGE, Mass., June 01, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological...
Voyager Therapeutics and CHDI Foundation Collaborate to Develop Novel Gene Therapy for Huntington’s Disease
September 12, 2016 07:05 ET
|
Voyager Therapeutics
CAMBRIDGE, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the...
Raptor Pharmaceutical Presents Results from Meta-Analysis Demonstrating Efficacy of QUINSAIR™ Comparable to Other Approved, Inhaled Antibiotics in Cystic Fibrosis Patients
September 07, 2016 03:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases,...
Raptor Pharmaceutical to Present Data on QUINSAIR™ and Other Inhaled Antibiotics at the ERS International Congress
August 24, 2016 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Aug. 24, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases,...